Table 1 Clinical trials currently testing NK cells as therapeutic agents in patients with solid tumors.*
From: NK cells and solid tumors: therapeutic potential and persisting obstacles
Indication(s) | Phase | Status | Nº | Source | Other regimens | Notes | Ref. |
|---|---|---|---|---|---|---|---|
Breast cancer | 1 | Recruiting | 20 | Allogenic | HER2 blockers IL2 | In patients with HER2+breast cancer | NCT05385705 |
Breast cancer Gastric cancer | 1 | Recruiting | 36 | Allogenic | Single agent | Off-the-shelf product targeting HER2+ tumors | NCT04319757 |
BTC | 2–3 | Recruiting | 128 | Allogenic | PD-1 blocker | Multi-arm study | NCT05429697 |
CRC | 1 | Not yet recruiting | 12 | Allogenic | IL2 TGFB1 blocker | Single-arm study | NCT05400122 |
CRC | 1 | Recruiting | 15 | Allogenic | Cetuximab | UCB-derived | NCT05040568 |
CRC | 1 | Recruiting | 18 | Autologous | Single agent | Expanded ex vivo by proprietary protocol | NCT05394714 |
CRC | 1 | Recruiting | 38 | N/A | Single agent | Engineered to express an NKG2D-like CAR | NCT05213195 |
CRC Sarcoma | 1 | Active, not recruiting | 14 | Allogenic | IL15R agonist | Single-arm study | NCT02890758 |
Gastric cancer | N/A | Recruiting | 18 | Allogenic | Single agent | UCB-derived | NCT04385641 |
GBM | 1 | Not yet recruiting | 25 | Allogenic | Single agent | UBC-derived, engineered to resist TGFB1 | NCT04991870 |
GBM | 1 | Recruiting | 5 | Autologous | Single agent | Intratumoral delivery | NCT05108012 |
GEJ tumors HNSCC | 2 | Recruiting | 55 | Allogenic | IL15R agonist PD-1 blocker | Engineered to express a PD-L1-targeting CAR | NCT04847466 |
GIST | 2 | Not yet recruiting | 1 | Autologous | DCs PD-1 blocker | Single-arm study | NCT05461235 |
Glioblastoma | 1 | Recruiting | 42 | Allogenic | PD-1 blocker | NK92 cell-based | NCT03383978 |
Glioma | 1 | Not yet recruiting | 24 | Autologous | Single agent | Single-arm study | NCT04254419 |
HCC | 1–2 | Recruiting | 200 | Allogenic | SOC | Multi-arm study | NCT04162158 |
HCC | 2 | Recruiting | 20 | Autologous | 5-fluorouracil Cisplatin | Single-arm study | NCT05040438 |
HCC | 2 | Recruiting | 35 | Allogenic | Apatinib PD-1 blocker | UCB-derived | NCT05171309 |
HNSCC | 1 | Recruiting | 12 | Allogenic | IL15R agonist CTLA4 blocker | Multi-arm study | NCT04290546 |
Neuroblastoma | 1 | Active, not recruiting | 13 | Autologous | GD2 blocker Lenalidomide | Single-arm study | NCT02573896 |
Neuroblastoma | 1 | Active, not recruiting | 85 | Allogenic | GD2 blocker IL2 | Single-arm study | NCT02650648 |
Neuroblastoma | 1–2 | Not yet recruiting | 31 | Autologous | GD2 blocker Irinotecan Temozolomide | Single-arm study | NCT04211675 |
Neuroblastoma | 2 | Active, not recruiting | 153 | Allogenic | SOC | In the context of HSCT | NCT01857934 |
Neuroblastoma Sarcoma | 2 | Active, not recruiting | 15 | Allogenic | Single agent | In the context of HSCT | NCT02100891 |
NSCLC | 1–2 | Recruiting | 24 | Allogenic | Single agent | Dose-finding study | NCT04616209 |
NSCLC | 1–2 | Recruiting | 24 | Autologous | Carboplatin Cetuximab Gemcitabine | Multi-arm study | NCT04872634 |
NSCLC | 1 | Enrolling by invitation | 5 | Allogenic | Single agent | NK92 cell-based | NCT03656705 |
NSCLC | 1 | Recruiting | 20 | Autologous | SOC | Including γδ T cells | NCT04990063 |
NSCLC | 1 | Recruiting | 21 | Allogenic | PD-L1 blocker | UCB-derived, engineered to express IL15 | NCT05334329 |
Prostate cancer | 1 | Recruiting | 9 | N/A | Single agent | Engineered to express a FOLH1-targeting CAR | NCT03692663 |
RTC | 1–2 | Recruiting | 40 | Autologous | Single agent | Engineered to express a CLDN6-targeting CAR | NCT05410717 |
Solid tumors | N/A | Recruiting | 60 | N/A | SOC | Multi-arm study | NCT04214730 |
Solid tumors | 1 | Active, not recruiting | 12 | Allogenic | IL2 PD-L1 blocker | Dose-escalation plus expansion phase | NCT04551885 |
Solid tumors | 1 | Active, not recruiting | 27 | Autologous | PD-1 blocker PD-L1 blocker | Expanded ex vivo by proprietary protocol | NCT03941262 |
Solid tumors | 1 | Not yet recruiting | 12 | Autologous | Single agent | Dose-finding study | NCT04557306 |
Solid tumors | 1 | Recruiting | 12 | N/A | Oncolytic virus | Trained immunity NK cells | NCT05271279 |
Solid tumors | 1 | Recruiting | 30 | Autologous | IL15R agonist | Memory-cytokine enriched NK cells | NCT04898543 |
Solid tumors | 1 | Recruiting | 37 | Allogenic | IL2 PD-1 blocker PD-L1 blocker | iPSC-derived | NCT03841110 |
Solid tumors | 1 | Recruiting | 38 | Allogenic | Cyclophosphamide Etoposide | UCB-derived | NCT03420963 |
Solid tumors | 1 | Recruiting | 40 | N/A | Single agent | Engineered to express a TPBG-targeting CAR | NCT05194709 |
Solid tumors | 1 | Recruiting | 40 | Autologous | Single agent | Including NKT cells and CTLs | NCT05237206 |
Solid tumors | 1 | Recruiting | 56 | Allogenic | Single agent | Engineered to express a TPBG-targeting CAR | NCT05137275 |
Solid tumors | 1 | Recruiting | 189 | Allogenic | Cetuximab HER2 blocker IL2 PD-1 blocker PD-L1 blocker | Combinatorial regimens based on tumor type | NCT05069935 |
Solid tumors | 1 | Recruiting | 322 | Allogenic | Cetuximab EGFR blocker HER2 blocker IL2 PD-1 blocker PD-L1 blocker | Combinatorial regimens based on tumor type | NCT05395052 |
Solid tumors | 1–2 | Recruiting | 60 | N/A | Decitabine | Post-remission | NCT05143125 |
Solid tumors | 1–2 | Recruiting | 200 | Autologous | Single agent | Activated ex vivo | NCT03634501 |